The main focus of the lab is to use organic chemistry, medicinal chemistry, and chemical biology to explore new strategies to interfere with and study processes related to cancer biology. This includes the development of small heterocyclic molecules but also new modalities in drug development such as oligonucleotides. The bioactive derivatives are designed using structure-based techniques or identified through screening-based strategies with Chemical Biology Consortium Sweden.
